Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand.

Tin Tin S, McKeage MJ, Khwaounjoo P, Thi AM, Elwood JM.

Cancer Epidemiol. 2018 Dec;57:24-32. doi: 10.1016/j.canep.2018.09.004. Epub 2018 Sep 29.

2.

The Effects of Synthetically Modified Natural Compounds on ABC Transporters.

Dantzic D, Noel P, Merien F, Liu DX, Lu J, Han H, McKeage MJ, Li Y.

Pharmaceutics. 2018 Aug 9;10(3). pii: E127. doi: 10.3390/pharmaceutics10030127. Review.

3.

Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test.

Shepherd P, Sheath KL, Tin ST, Khwaounjoo P, Aye PS, Li A, Laking GR, Kingston NJ, Lewis CA, Mark Elwood J, Love DR, McKeage MJ.

Oncotarget. 2017 Sep 16;8(60):101437-101451. doi: 10.18632/oncotarget.21023. eCollection 2017 Nov 24.

4.

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L, Hughes BGM.

Target Oncol. 2018 Feb;13(1):89-98. doi: 10.1007/s11523-017-0543-0.

PMID:
29188408
5.

Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation.

Han CH, Khwaounjoo P, Hill AG, Miskelly GM, McKeage MJ.

Sci Rep. 2017 Jun 22;7(1):4073. doi: 10.1038/s41598-017-04383-4.

6.

Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity.

Cui H, Zhang AJ, McKeage MJ, Nott LM, Geraghty D, Guven N, Liu JJ.

J Inorg Biochem. 2017 Dec;177:249-258. doi: 10.1016/j.jinorgbio.2017.04.022. Epub 2017 Apr 25.

PMID:
28551160
7.

Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics.

Han CH, Kilfoyle DH, Hill AG, Jameson MB, McKeage MJ.

Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1479-1490. Epub 2016 Aug 23. Review.

PMID:
27539508
8.

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

Yosaatmadja Y, Silva S, Dickson JM, Patterson AV, Smaill JB, Flanagan JU, McKeage MJ, Squire CJ.

J Struct Biol. 2015 Dec;192(3):539-544. doi: 10.1016/j.jsb.2015.10.018. Epub 2015 Nov 2.

PMID:
26522274
9.

Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity.

Yan F, Liu JJ, Ip V, Jamieson SM, McKeage MJ.

J Neurochem. 2015 Dec;135(6):1099-112. doi: 10.1111/jnc.13355. Epub 2015 Oct 28.

10.

Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs.

Leung EY, Kim JE, Askarian-Amiri M, Joseph WR, McKeage MJ, Baguley BC.

Front Oncol. 2014 Sep 3;4:221. doi: 10.3389/fonc.2014.00221. eCollection 2014.

11.

Emerging roles of metal solute carriers in cancer mechanisms and treatment.

Jong NN, McKeage MJ.

Biopharm Drug Dispos. 2014 Nov;35(8):450-62. doi: 10.1002/bdd.1903. Epub 2014 Sep 5. Review.

PMID:
24889085
12.

Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent.

Chen YY, Lukka PB, Joseph WR, Finlay GJ, Paxton JW, McKeage MJ, Baguley BC.

Cancer Chemother Pharmacol. 2014 Jul;74(1):25-35. doi: 10.1007/s00280-014-2469-x. Epub 2014 May 7.

PMID:
24801172
13.

Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.

Han CH, Khwaounjoo P, Kilfoyle DH, Hill A, McKeage MJ.

BMC Cancer. 2013 Oct 25;13:495. doi: 10.1186/1471-2407-13-495.

14.

Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo.

Ip V, Liu JJ, McKeage MJ.

Clin Exp Pharmacol Physiol. 2013 Jun;40(6):371-8. doi: 10.1111/1440-1681.12088.

PMID:
23556474
15.

Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons.

Liu JJ, Kim Y, Yan F, Ding Q, Ip V, Jong NN, Mercer JF, McKeage MJ.

Biochem Pharmacol. 2013 Jan 15;85(2):207-15. doi: 10.1016/j.bcp.2012.10.023. Epub 2012 Nov 1.

PMID:
23123662
16.

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.

McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, Melink TJ, Tchekmedyian NS.

BMC Cancer. 2012 Oct 25;12:496. doi: 10.1186/1471-2407-12-496.

17.

Membrane transporters as determinants of the pharmacology of platinum anticancer drugs.

Liu JJ, Lu J, McKeage MJ.

Curr Cancer Drug Targets. 2012 Oct;12(8):962-86. Review.

PMID:
22794121
18.

Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.

McKeage MJ, Jameson MB; AS1404-201 Study Group Investigators.

J Thorac Dis. 2010 Dec;2(4):199-204. doi: 10.3978/j.issn.2072-1439.2010.02.04.1.

19.

Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial.

McKeage MJ, Fong PC, Hong X, Flarakos J, Mangold J, Du Y, Tanaka C, Schran H.

Cancer Chemother Pharmacol. 2012 May;69(5):1145-54. doi: 10.1007/s00280-011-1809-3. Epub 2012 Jan 3.

PMID:
22212299
20.

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.

McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, Jameson MB.

BMC Cancer. 2011 Oct 7;11:432. doi: 10.1186/1471-2407-11-432.

21.

Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.

Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G.

J Clin Oncol. 2011 Aug 1;29(22):2965-71. doi: 10.1200/JCO.2011.35.0660. Epub 2011 Jun 27.

PMID:
21709202
22.

Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.

McKeage MJ.

Clin Lung Cancer. 2011 May;12(3):143-7. doi: 10.1016/j.cllc.2011.03.010. Epub 2011 Apr 22. Review.

PMID:
21663855
23.

Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.

Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ.

J Pharmacol Exp Ther. 2011 Aug;338(2):537-47. doi: 10.1124/jpet.111.181297. Epub 2011 May 23.

PMID:
21606177
24.

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.

Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, Acton G, Erlandsson F, Spicer JF.

Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. doi: 10.1158/1078-0432.CCR-10-2490. Epub 2011 Mar 29.

25.

ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.

Baguley BC, McKeage MJ.

Future Oncol. 2010 Oct;6(10):1537-43. doi: 10.2217/fon.10.122. Review.

PMID:
21062153
26.

Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue.

Ip V, Liu JJ, Mercer JF, McKeage MJ.

Mol Pain. 2010 Sep 13;6:53. doi: 10.1186/1744-8069-6-53.

27.

Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.

Hill A, Bergin P, Hanning F, Thompson P, Findlay M, Damianovich D, McKeage MJ.

BMC Cancer. 2010 Aug 23;10:451. doi: 10.1186/1471-2407-10-451.

28.

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

McKeage MJ, Baguley BC.

Cancer. 2010 Apr 15;116(8):1859-71. doi: 10.1002/cncr.24975. Review.

29.

Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.

Jamieson SM, Subramaniam J, Liu JJ, Jong NN, Ip V, Connor B, McKeage MJ.

Mol Pain. 2009 Nov 18;5:66. doi: 10.1186/1744-8069-5-66.

30.

Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.

Liu JJ, Jamieson SM, Subramaniam J, Ip V, Jong NN, Mercer JF, McKeage MJ.

Cancer Chemother Pharmacol. 2009 Sep;64(4):847-56. doi: 10.1007/s00280-009-1017-6. Epub 2009 May 24.

PMID:
19466412
31.

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J.

Lung Cancer. 2009 Aug;65(2):192-7. doi: 10.1016/j.lungcan.2009.03.027. Epub 2009 May 5.

PMID:
19409645
32.

Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

Jameson MB, Sharp DM, Sissingh JI, Hogg CR, Thompson PI, McKeage MJ, Jeffery M, Waller S, Acton G, Green C, Baguley BC.

Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2553-9. doi: 10.1167/iovs.08-2068. Epub 2009 Apr 22.

PMID:
19387077
33.

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E.

Br J Cancer. 2008 Dec 16;99(12):2006-12. doi: 10.1038/sj.bjc.6604808.

34.

Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.

Bell DN, Liu JJ, Tingle MD, Rattel B, Meyer TU, McKeage MJ.

Clin Exp Pharmacol Physiol. 2008 Dec;35(12):1440-6. doi: 10.1111/j.1440-1681.2008.05017.x. Epub 2008 Jul 29.

PMID:
18671714
35.

Antitumor activity of gold(i), silver(i) and copper(i) complexes containing chiral tertiary phosphines.

McKeage MJ, Papathanasiou P, Salem G, Sjaarda A, Swiegers GF, Waring P, Wild SB.

Met Based Drugs. 1998;5(4):217-23. doi: 10.1155/MBD.1998.217.

36.

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.

McKeage MJ.

Expert Opin Investig Drugs. 2008 Jan;17(1):23-9. Review.

PMID:
18095916
37.

In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.

Liu JJ, Galettis P, Farr A, Maharaj L, Samarasinha H, McGechan AC, Baguley BC, Bowen RJ, Berners-Price SJ, McKeage MJ.

J Inorg Biochem. 2008 Feb;102(2):303-10. Epub 2007 Sep 26.

PMID:
18029019
38.

Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel.

Jamieson SM, Liu JJ, Connor B, Dragunow M, McKeage MJ.

Neurotoxicology. 2007 Nov;28(6):1092-8. Epub 2007 May 21.

PMID:
17686523
40.

Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.

Liu JJ, Ching LM, Goldthorpe M, Sutherland R, Baguley BC, Kirker JA, McKeage MJ.

Cancer Chemother Pharmacol. 2007 Apr;59(5):661-9. Epub 2006 Aug 31.

PMID:
16944150
41.

Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry.

Bell DN, Liu JJ, Tingle MD, McKeage MJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jun 6;837(1-2):29-34. Epub 2006 May 11.

PMID:
16697278
42.

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB.

Clin Cancer Res. 2006 Mar 15;12(6):1776-84.

43.

Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro.

Carr JL, Tingle MD, McKeage MJ.

Cancer Chemother Pharmacol. 2006 Apr;57(4):483-90. Epub 2005 Sep 20.

PMID:
16172904
44.

New-generation platinum drugs in the treatment of cisplatin-resistant cancers.

McKeage MJ.

Expert Opin Investig Drugs. 2005 Aug;14(8):1033-46. Review.

PMID:
16050795
45.

Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss.

Jamieson SM, Liu J, Connor B, McKeage MJ.

Cancer Chemother Pharmacol. 2005 Oct;56(4):391-9. Epub 2005 May 11.

PMID:
15887017
46.

Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients.

Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, Isaacs R, McKeage MJ.

Clin Exp Pharmacol Physiol. 2004 Oct;31(10):677-82.

PMID:
15554907
47.

Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity.

Jamieson SM, Liu J, Hsu T, Baguley BC, McKeage MJ.

Br J Cancer. 2003 Jun 16;88(12):1942-7.

48.

Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR.

Cancer Chemother Pharmacol. 2003 Jan;51(1):43-52. Epub 2002 Nov 12.

PMID:
12497205
49.

Gold opens mitochondrial pathways to apoptosis.

McKeage MJ.

Br J Pharmacol. 2002 Aug;136(8):1081-2. No abstract available.

50.

Supplemental Content

Loading ...
Support Center